---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-011557"
form_type: "8-K/A"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T16:22:05.311890+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Arrowhead appoints Hongbo Lu to board; board expands to eight, effective March 15

## Summary
- Hongbo Lu appointed to Arrowhead Board; board expanded from seven to eight, effective March 15, 2024.
- Dr. Lu receives sign-on RSU grant of $761,666, vesting over three years.
- Dr. Lu will receive standard non-employee director compensation as described in the 2024 proxy statement.
- Dr. Lu has no family relationships with executives and no material interest in any related-party transactions.

## SEC filing metadata
- accession: 0001628280-24-011557
- form_type: 8-K/A
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828024011557/0001628280-24-011557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828024011557/arwr-20240221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-011557
- JSON: https://secwatch.observer/filing/0001628280-24-011557.json
- Plain text: https://secwatch.observer/filing/0001628280-24-011557.txt

## Key facts
- Executive change
  Hongbo Lu was appointed as Director at ARROWHEAD PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Director
  source text: Appointment of Hongbo Lu as a Director
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828024011557/0001628280-24-011557-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.